Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiromi Tanimura

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cancer Letters|September 20, 2017
MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitorSatoshi Aida, Yukiko Sonobe, Hiromi Tanimura, et al.
Molecular Cancer Therapeutics|September 18, 2020
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S MutationKenji Kashima, Hiroki Kawauchi, Hiromi Tanimura, et al.
International Journal of Cancer|July 17, 2003
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889Mika Endo, Masanori Miwa, Hiroyuki Eda, et al.
Scientific Reports|February 27, 2025
Development of a novel postoperative adhesion induction model in cynomolgus monkeys with high reliability and reproducibilityKenji Nakagawa, Masaki Yamazaki, Hiromi Tanimura, et al.
Bioorganic & Medicinal Chemistry Letters|March 6, 2003
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabineKazuo Hattori, Yasunori Kohchi, Nobuhiro Oikawa, et al.
Molecular Cancer Therapeutics|September 23, 2018
Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven CancerHiroshi Tanaka, Hitoshi Sase, Toshiyuki Tsukaguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutationsHiroshi Tanaka, Miyuki Yoshida, Hiromi Tanimura, et al.
Science Translational Medicine|February 22, 2023
A long-acting anti-IL-8 antibody improves inflammation and fibrosis in endometriosisAyako Nishimoto-Kakiuchi, Izumi Sato, Kiyotaka Nakano, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2009
A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenograftsMika Endo, Masanori Miwa, Masako Ura, et al.
Cancer Research|August 9, 2019
YES1 Is a Targetable Oncogene in Cancers Harboring <i>YES1</i> Gene AmplificationNatsuki Hamanaka, Yoshito Nakanishi, Takakazu Mizuno, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cancer Letters|September 20, 2017
MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitorSatoshi Aida, Yukiko Sonobe, Hiromi Tanimura, et al.
Molecular Cancer Therapeutics|September 18, 2020
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S MutationKenji Kashima, Hiroki Kawauchi, Hiromi Tanimura, et al.
International Journal of Cancer|July 17, 2003
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889Mika Endo, Masanori Miwa, Hiroyuki Eda, et al.
Scientific Reports|February 27, 2025
Development of a novel postoperative adhesion induction model in cynomolgus monkeys with high reliability and reproducibilityKenji Nakagawa, Masaki Yamazaki, Hiromi Tanimura, et al.
Bioorganic & Medicinal Chemistry Letters|March 6, 2003
Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabineKazuo Hattori, Yasunori Kohchi, Nobuhiro Oikawa, et al.
Molecular Cancer Therapeutics|September 23, 2018
Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven CancerHiroshi Tanaka, Hitoshi Sase, Toshiyuki Tsukaguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutationsHiroshi Tanaka, Miyuki Yoshida, Hiromi Tanimura, et al.
Science Translational Medicine|February 22, 2023
A long-acting anti-IL-8 antibody improves inflammation and fibrosis in endometriosisAyako Nishimoto-Kakiuchi, Izumi Sato, Kiyotaka Nakano, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2009
A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenograftsMika Endo, Masanori Miwa, Masako Ura, et al.
Cancer Research|August 9, 2019
YES1 Is a Targetable Oncogene in Cancers Harboring <i>YES1</i> Gene AmplificationNatsuki Hamanaka, Yoshito Nakanishi, Takakazu Mizuno, et al.
Pageof 2